$TTPH News
Last published 6y ago
- 6y agoLJPCTTPHLa Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.GlobeNewswireLa Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights Combined company will offer two innovative...
- 6y agoTTPHLa Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.Business WireSAN DIEGO & WATERTOWN, Mass.--(BUSINESS WIRE)--La Jolla Pharmaceutical Company, which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, and Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ to treat serious and ...
- 6y agoTTPHTetraphase Announces Receipt of Proposal from La Jolla Pharmaceutical Company, Determination of Superior Offer and Notice to MelintaBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today announced that on June 19, 2020, its Board of Directors received an unsolicited proposal from La Jolla Pharmaceutical Company (“La Jolla”) to acq ...
- 6y agoTTPHMelinta Therapeutics to Acquire Tetraphase PharmaceuticalsBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ to treat serious and life-threatening infections, today announced that it has entered into a definitive merger agreement with Melinta Therapeutics, Inc. (“Melinta”), pursuant to which Melinta would acquire Tetraphase, through a te ...
- 6y agoTTPHTetraphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRxBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection) to treat serious and life-threatening infections, today announced that its Board of Directors has received a revised proposal from Melinta Therapeutics, Inc. (“Melinta”) amending its prior proposal to a ...
- 6y agoTTPHTetraphase Announces Second Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased ConsiderationBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today announced that it has entered into a second amendment to the Agreement and Plan of Merger, dated March 15, 2020, asamended on May 27, 2020, to wh ...
- 6y agoACRXTTPHAcelRx Pharmaceuticals Announces Revised Merger Agreement with TetraphasePR NewswireAcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of...
- 6y agoTTPHTetraphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRxBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today announced that its Board of Directors has received a revised proposal from Melinta Therapeutics, Inc. (“Melinta”) amending its prior proposal to ...
- 6y agoACRXTTPHAcelRx Pharmaceuticals Announces Revised Merger Agreement with TetraphasePR NewswireAcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of...
- 6y agoTTPHTetraphase Announces Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased ConsiderationBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection) to treat serious and life-threatening infections, today announced that it has entered into an amendment to the Agreement and Plan of Merger, dated March 15, 2020, to which the Company is a party with Ac ...
- 6y agoTTPHTetraphase Announces Determination of Superior Offer and Notice to AcelRxBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline Xerava™ (eravacycline for injection) to treat serious and life-threatening infections, today announced that its Board of Directors has determined that the latest proposal from Melinta Therapeutics, Inc. (“Melinta”) to acquire the Company i ...
- 6y agoSDGRTTPHTORCSchrödinger Strengthens Board of Directors with Appointments of Jeffrey Chodakewitz, M.D., and Gary GinsbergBusiness WireNEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced the appointments of Jeffrey A. Chodakewitz, M.D., and Gary Ginsberg to its Board of Directors. Dr. Chodakewitz is a veteran in the biopharmaceutical industry who previously held leadership roles at Vertex Pha ...
- 6y agoDLPHCSFLTTPHFSCTMoore Kuehn Encourages DLPH, CSFL, TTPH, and FSCT Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning...
- 6y agoTTPHACRXTetraphase Pharmaceuticals and AcelRx Pharmaceuticals Enter into Definitive Merger AgreementBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA to treat serious and life-threatening infections, today announced the execution of a definitive merger agreement pursuant to which AcelRx Pharmaceuticals (Nasdaq: ACRX) would acquire Tetraphase in a stock for stock transaction. Und ...
- 6y agoTTPHTetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Achievements and Key 2020 MilestonesBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA to treat serious and life-threatening infections, today reported financial results for the fourth quarter and year ended December 31, 2019, provided an overview of recent achievements, and highlighted key milestones for 2020.
- 6y agoTTPHNew patent application published for: Tetracycline CompoundsUS Patent Applications (USPTO)( 1 of 1 )
- 6y agoTTPHTetraphase Pharmaceuticals Announces $17.5 Million of Financings Priced At-the-MarketBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today announced that it has entered into a definitive agreement with Armistice Capital, LLC, a healthcare-focused institutional investor, for the purc ...
- 7y agoTTPHTetraphase Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate DevelopmentsBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection) to treat serious and life-threatening infections, today reported financial results for the third quarter ended September 30, 2019.
- 7y agoTTPHTetraphase Pharmaceuticals Announces Completion of $8 Million Registered Direct Offering Priced At-the-MarketBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection) to treat serious and life-threatening infections, today announced the completion of its previously announced registered direct offering to a healthcare-focused institutional investor priced at-the-marke ...
- 7y agoTTPHTetraphase Pharmaceuticals Announces $8 Million Registered Direct Offering Priced At-the-MarketBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today announced that it has entered into a definitive agreement with a healthcare-focused institutional investor for the purchase, in a registered dire ...
- 7y agoTTPHTetraphase Pharmaceuticals Announces Reverse Stock SplitBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, announced today that it will effect a 1-for-20 reverse stock split of its common stock that will be effective at 5:00 p.m. Eastern Time today. The Com ...
- 7y agoTTPHTetraphase Pharmaceuticals to Present XERAVA™ (Eravacycline) Data at IDWeek 2019Business WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection) to treat serious and life-threatening infections, today announced that data on XERAVA will be featured in seven poster presentations at the Infectious Disease Society of America’s (IDSA) Infectious Dise ...
- 7y agoTTPHTetraphase Pharmaceuticals to Present at the H.C. Wainwright Global Investment ConferenceBusiness WireWATERTOWN, Mass--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today announced that senior management will present a corporate overview at the H. C. Wainwright and Company 21st Annual Global Investment Conference on ...
- 7y agoTTPHTetraphase Pharmaceuticals, Inc. (TTPH) CEO Larry Edwards on Q2 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
- 7y agoTTPHTetraphase Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Corporate DevelopmentsBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today reported financial results for the second quarter ended June 30, 2019.
- 7y agoTTPHTetraphase Pharmaceuticals to Host Second Quarter 2019 Financial Results Conference CallBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that company management will host a conference call at 4:30 p.m. ET on Thursday, August 8, 2019 to discuss the Company’s second quarter 2019 financial results and provide a gen ...
- 7y agoTTPHNew Studies Highlight Activity of XERAVA™ Against Gram-Negative and Gram-Positive Clinical Isolates, Including Multidrug-Resistant PathogensBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing novel tetracyclines to treat serious and life-threatening conditions, announced the presentation of new data on XERAVA™ (eravacycline), a novel, fully synthetic fluorocycline approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agen ...
- 7y agoTTPHTetraphase Pharmaceuticals Highlights Data at Upcoming American Society for Microbiology Microbe 2019 Annual MeetingBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that new data will be presented at the American Society for Microbiology (ASM) Microbe 2019 Annual Meeting, taking place June 20-24 in San Francisco. Presentatio ...
- 7y agoTTPHTetraphase Pharmaceuticals Announces Corporate Reorganization Aimed at Maximizing XERAVA™ (Eravacycline) Commercial OpportunityBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), (“Tetraphase” or “the Company”) today announced a corporate reorganization in order to maximize the commercial opportunity for XERAVA™ (eravacycline), the Company’s novel tetracycline antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older. Thi ...
- 7y agoTTPHTetraphase Pharmaceuticals Announces New XERAVA™ (eravacycline) Data at the 39th Annual Surgical Infection Society MeetingBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced the presentation of positive data from three studies further evaluating its lead compound, XERAVA™ (eravacycline), a novel, fully-synthetic fluorocycline, approv ...
- 7y agoTTPHTetraphase Pharmaceuticals, Inc. (TTPH) CEO Guy Macdonald on Q4 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 10y agoTTPHTetraphase Pharmaceuticals' (TTPH) CEO Guy Macdonald On Eravacycline Regulatory And Development Status Conference (Transcript)Earnings Call Transcripts
- 10y agoTTPHTetraphase Pharmaceuticals' (TTPH) CEO Guy Macdonald on Q4 2015 Results - Earnings Call TranscriptEarnings Call Transcripts